Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24945628 | 0.92 | GPR119 (0.44) | GPR119CHRM1CHRM2BCHECHRM4 | |
| SCHEMBL24945787 | 0.92 | GPR119 (0.52) | GPR119CHRM1CHRM2CHRM4 | |
| SCHEMBL24945738 | 0.92 | GPR119 (0.52) | GPR119CHRM1CHRM2 | |
| SCHEMBL24945613 | 0.91 | HTR2A (0.45) | GPR119CHRM1CHRM2BCHECHRM4 | |
| SCHEMBL24945616 | 0.91 | GPR119 (0.43) | GPR119CHRM1CHRM2BCHECHRM4 | |
| SCHEMBL24945611 | 0.90 | GPR119 (0.42) | GPR119CHRM1CHRM2BCHECHRM4 | |
| SCHEMBL23744619 | 0.88 | CHRM4 (0.53) | CHRM1CHRM2BCHECHRM4CHRM3 | |
| SCHEMBL24945619 | 0.88 | GPR119 (0.44) | GPR119CHRM1CHRM2BCHECHRM4 | |
| SCHEMBL31492274 | 0.87 | GPR119 (0.49) | GPR119CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL23744226 | 0.86 | CHRM2 (0.56) | CHRM1CHRM2CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023010078-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-02-02 | — | — | WO | disclosed |